Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

J. L. Xu1, B. Jin1, Z. H. Ren2, Y. Q. Lou1, Z. R. Zhou3, Q. Z. Yang4, B. H. Han1*

1 Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China, 2 The Ninth People's Hospital of Shanghai, Shanghai Jiaotong University, Shanghai, China, 3 Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College, Shanghai, China, 4 Department of Gynecology, Women and Child Care of Heyuan, Guangdong, China

* xkyyhan@gmail.com

Abstract

Background

Whether a combination of chemotherapy and erlotinib is beneficial for advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to summarize the currently available evidence and compare the efficacy and safety of chemotherapy plus erlotinib versus chemotherapy alone for treating advanced NSCLC.

Methods

EMBASE, PubMed, and the Cochrane Central Register of Controlled Trials were searched for relevant studies. Our protocol was registered in PROSPERO (CRD42014015015).

Results

Nine randomized controlled trials with a total of 3599 patients were included. Compared to chemotherapy alone, chemotherapy plus erlotinib was superior in PFS (HR = 0.76 [95% CI 0.62, 0.92], P = 0.006), and no statistically significant difference was observed in OS (HR = 0.94 [95% CI 0.86, 1.03], P = 0.16). Intercalated erlotinib plus chemotherapy demonstrated improvements in PFS (HR = 0.67 [95% CI 0.50, 0.91], P = 0.009) and OS (HR = 0.82 [95% CI 0.69, 0.98], P = 0.03). Continuous erlotinib plus chemotherapy treatment failed to demonstrate improvements in PFS (HR = 0.91 [95% CI 0.80, 1.04], P = 0.16) and OS (HR = 0.98 [95% CI 0.89, 1.09], P = 0.75). The association of chemotherapy plus erlotinib with improvement in PFS was significant in never smoking patients (HR = 0.46 [95% CI 0.37, 0.56], P<0.0001) but not in smoking patients (HR = 0.70 [95% CI 0.49, 1.00], P = 0.05). Among patients with EGFR mutant tumors, chemotherapy plus erlotinib demonstrated significant improvements in PFS (HR = 0.31 [95% CI 0.17, 0.58], P = 0.0002) and OS (HR = 0.52 [95% CI 0.30, 0.88], P = 0.01). Among patients with EGFR wild-type tumors, no statistically significant difference was observed with respect to PFS (HR = 0.87 [95% CI 0.70, 1.08], P = 0.21) and OS (HR = 0.78 [95% CI 0.59, 1.01], P = 0.06).
Conclusion

Combination of chemotherapy and erlotinib is a viable treatment option for patients with NSCLC, especially for patients who never smoked and patients with EGFR mutation-positive disease. In addition, intercalated administration is an effective combinatorial strategy.

Introduction

Lung cancer is the most common cause of cancer-related deaths worldwide [1], and approximately 85 to 90% of all lung cancer cases are non-small cell lung cancer (NSCLC). More than 70% of lung cancer cases are diagnosed at an advanced stage, which means that surgery is not an option for most of these patients [1, 2]. Furthermore, chemotherapy alone fails to provide patients with significant effects in overall survival [3, 4]. Drug resistance is one of the major reasons why patients fail to benefit from chemotherapy as most patients’ tumors quickly develop acquired resistance to chemotherapeutic drugs [5, 6].

Erlotinib is an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and has been considered as the standard treatment for patients with EGFR mutant tumors. It was demonstrated that EGFR-TKIs could prolong overall survival in EGFR-unselected patients with NSCLC [7]. In the last decade, several studies evaluated EGFR-TKIs in combination with standard chemotherapy for patients with advanced NSCLC [8–17]. Continuous erlotinib in combination with carboplatin based chemotherapy failed to demonstrate a survival advantage over carboplatin based chemotherapy alone in patients with previously untreated advanced NSCLC [16]. The GFPC 10.02 study also showed that intercalated erlotinib in combination with docetaxel was not more effective than docetaxel alone as a second-line treatment for advanced NSCLC with wild-type or unknown EGFR status [10]. Some experts believe that EGFR-TKIs cause a G1 cell-cycle arrest, which can inhibit the cell-cycle-dependent cytotoxic effects of chemotherapy [18]. However, a multicenter phase II trial showed the superior efficacy of the combination of pemetrexed and erlotinib over pemetrexed alone [13]. FASTACT-2 [11], a phase III study, also showed significant improvement in efficacy with an intercalated regimen of chemotherapy and an EGFR-TKI for patients with advanced NSCLC. Whether the combination of chemotherapy and erlotinib is beneficial for advanced NSCLC remains controversial. It is also unclear which population of patients may gain the greatest benefit from this combinatorial approach. Therefore, we performed this meta-analysis of randomized clinical trials to assess the efficacy and safety of erlotinib in combination with standard chemotherapy versus chemotherapy alone for the treatment of patients with advanced NSCLC and explore whether the outcomes vary by different patient subgroups.

Materials and Methods

The methods are based on our previously described protocol [19]. We conducted this meta-analysis with the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement [20].

Search strategy

Two authors (Ren ZH, Xu JL) independently carried out a comprehensive systematic search for published articles from inception to October 22, 2014 using the PubMed, EMBASE, and Cochrane databases. Moreover, we searched the ClinicalTrials.gov website for information
about registered randomized controlled clinical trials (RCTs). The search was limited to articles published in English. We resolved any disagreements through discussion with a third person (Han BH). The following search items were used: ("Randomized Controlled Trials as Topic"[Mesh] OR Randomized Controlled Trial [Publication Type]) OR random AND ("Lung Neoplasms"[Mesh] OR nsclc OR non-small cell OR lung neoplasm OR lung tumor OR lung carcinoma OR lung cancer) AND ("Tarceva" OR erlotinib [Title/Abstract] OR "erlotinib" [Supplementary Concept]). The references from the included studies and previous meta-analyses were also manually examined.

Eligibility criteria
The inclusion criteria were as follows: 1. Randomized controlled clinical trials; 2. Studies comparing erlotinib plus standard chemotherapy to standard chemotherapy alone; 3. At least one of the two endpoints (PFS, OS) was reported. The exclusion criteria were as follows: 1. Single arm studies; 2. Observational cohort studies; 3. Erlotinib was given after chemotherapy was completed or chemotherapy was given after erlotinib was discontinued. 4. Maintenance therapy studies. When duplicate publications were identified, the most complete reports were included.

Quality assessment
Two authors (Zhou ZR, Xu JL) independently assessed the quality of the trials using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions, which appraised sequence generation, allocation concealment, performance bias, detection bias, attrition bias, reporting bias, and other biases. Disagreements between reviewers were resolved by discussion with a third person (Jin B).

Data collection
Two authors (Yang QZ, Xu JL) independently extracted data about the first author, year of publication, treatment comparison, drug delivery, regimens of each arm, the number of patients enrolled, age, hazard ratios (HR) and 95% confidence intervals (CI) for progression free survival (PFS) and overall survival (OS), median PFS and median OS, and adverse events (AEs). If HRs were not directly reported, we contacted the authors of the primary studies for additional data. If we were unable to contact the authors, we extracted data from survival curves [21].

Statistical analysis and publication bias
Two authors (Lou YQ, Xu JL) performed the statistical analyses. A fixed-effect meta-analysis was used to calculate pooled HRs for PFS and OS, and OR for AEs, together with 95% CIs. We assessed the presence of statistical heterogeneity among the studies by using the Q statistic, and the magnitude of heterogeneity was assessed using the $I^2$ statistic. If statistical heterogeneity was detected, in which $P<0.10$ or $I^2$ was more than 50%, a random-effect meta-analysis was used. It was explored by subgroup analysis as follows: smoking or not, ethnicity, intercalated therapy (receiving chemotherapy with intercalated erlotinib) or continuous therapy (receiving chemotherapy with continuous erlotinib), EGFR-mutant or EGFR wild-type. The meta-analysis results were displayed as forest plots. All calculations were performed using the Review Manager 5.3. Publication bias was assessed by the construction of funnel plots.
Results

Eligible studies

A total of 1597 articles were identified by the initial search strategy. After excluding irrelevant studies, review articles, RCTs without adequate data, meta-analyses, observational studies, single arm trials and case reports, nine trials were finally included for this meta-analysis (S1 File shows a list of full-text excluded articles). The selection steps are summarized in the flow chart shown in Fig 1. These trials enrolled a total of 3599 patients. Among them [8–16], four trials were placebo-controlled double-blinded trials [11, 14–16]. Five trials used intercalated erlotinib plus chemotherapy as the drug delivery method, while other four trials used continuous erlotinib plus chemotherapy treatment. Three trials enrolled an Asian-dominant population [11, 13,
Table 1. Summary of Characteristics of the Included Studies. Abbreviations: E: erlotinib, Carb: carboplatin, Cisp: cisplatin, Pac: paclitaxel, Gem: Gemcitabine, Pem: Pemetrexed, NA: Not available

| Study      | Number of points | Dominant ethnicity | Female | Age (range) | Drug delivery | Treatment comparison | Non-smoker | EGFR-mutant | EGFR-wild-type |
|------------|------------------|--------------------|--------|-------------|---------------|----------------------|------------|-------------|---------------|
| Herbst, 2005 | 1079             | Caucasian/934      | 424    | 24–84       | Continuous    | E+Carb+Pac vs. Carb+Pac +Placebo | 116        | 29          | 198           |
| Gatzemeier, 2007 | 1159        | Caucasian/1064     | 267    | 26–84       | Continuous    | E+Gem+Cisp vs. Gem +Cisp+Placebo | NA        | NA          | NA            |
| Mok, 2009    | 154              | Asian/145          | 46     | 27–79       | Intercalated  | E+Gem+Cisp or Carb vs. Gem+Cisp or Carb +Placebo | 52        | NA          | NA            |
| Thomas, 2013 | 146              | NA                 | 73     | 69–90       | Continuous    | E+Gem vs. E vs. Gem            | 240        | 24          | 19            |
| Lee, 2013    | 240              | Asian/240          | 157    | NA          | Intercalated  | E+Pem vs. E vs. Pem           | 219        | 97          | 136           |
| Wu, 2013     | 451              | Asian/451          | 179    | 31–96       | Intercalated  | E+Gem+Cisp or Carb vs. Gem+Cisp or Carb +Placebo | 219        | 97          | 136           |
| Dittrich, 2014 | 165            | Caucasian/157      | 64     | 31–84       | Continuous    | E+Pem vs. E vs Pem            | 24         | NA          | NA            |
| Auliac, 2014 | 151              | NA                 | 115    | NA          | Intercalated  | E+docetaxel vs. E vs. docetaxel | 11         | NA          | 98            |
| Michael, 2014 | 54              | Caucasian/49       | 22     | 38–86       | Intercalated  | E+Gem vs. Gem               | 8          | NA          | NA            |

doi:10.1371/journal.pone.0131278.t001

Risk of bias and publication bias assessment

Although all nine eligible trials reported that the participants were randomized into different treatment arms, three of them did not provide details about random sequence generation [12, 15, 16]. Only one trial showed concealment procedures [11]. Five trials were open-label, they did not mask either participants or personnel [8–10, 12, 13]. Five trials had independent persons who performed the outcome assessment [10, 11, 14–16], and one trial did not show details about the blinding of outcome assessment [12]. Six eligible trials conducted efficacy analysis on an intention-to-treat basis [8, 11, 13–16]; one trial missed two cases in both arms [10]; and one trial missed three patients who were still in treatment [9]. We believe that the outcomes were unlikely to have been affected in these instances. Six trials did not selectively report data [8–13], while the protocols of three trials were not available [14–16]. Therefore, we could not judge whether these three trials selectively reported data. No significant publication bias was detected for any of the measured outcomes by funnel plots.

http://www.sciencedirect.com/science/article/pii/S1525730411002105 - bib22, while other six trials enrolled a Caucasian-dominant population [8–10, 12, 15, 16]. One trial only enrolled patients who never smoked [13]. Five studies compared gemcitabine based chemotherapy plus erlotinib versus gemcitabine based chemotherapy alone [8, 11, 12, 14, 15], two trials compared pemetrexed and erlotinib with either pemetrexed or erlotinib alone [9, 13], one trial compared erlotinib plus docetaxel versus erlotinib or docetaxel alone [10], and one assessed erlotinib plus paclitaxel based chemotherapy versus paclitaxel based chemotherapy alone [16]. One trial did not show HRs for PFS or OS [22], but later it was showed in another article [12]. In three studies, the EGFR mutation status was confirmed in 601 patients [11, 13, 16]. One of these three studies reported data for subgroup analysis according to mutation status [11], one reported them in another article [23], and one did not provide enough data [13]. The characteristics of eligible studies are summarized in Table 1.
Progression free survival

This meta-analysis showed a longer PFS in patients who received a combination of erlotinib and chemotherapy treatment (HR = 0.76 [95% CI 0.62, 0.92], P = 0.006) (Fig 2). The heterogeneity between studies was significant [χ² = 14.28, df = 4 (P = 0.006); I² = 72%] (Fig 2). The pooled HR meta-analysis for intercalated erlotinib plus chemotherapy showed an improvement in PFS (HR = 0.67 [95% CI 0.50, 0.91], P = 0.009) (Fig 3). Meanwhile, continuous erlotinib plus chemotherapy treatment failed to show an improvement in PFS (HR = 0.91 [95% CI 0.80, 1.04], P = 0.16) (Fig 3). Subgroup analysis demonstrated improvements in PFS in never smoking patients (HR = 0.46 [95% CI 0.37, 0.56], P < 0.0001) and patients with EGFR mutant tumors (HR = 0.31 [95% CI 0.17, 0.58], P = 0.0002) (Fig 3). No significant difference was shown in PFS between the chemotherapy plus erlotinib group and the chemotherapy group in patients with EGFR wild-type tumors (HR = 0.87 [95% CI 0.70, 1.08], P = 0.21) (Fig 3). In addition, smokers (current or previous) did not obtain a statistically significant benefit from erlotinib plus chemotherapy (HR = 0.70 [95% CI 0.49, 1.00], P = 0.05) (Fig 3).

Overall survival

HRs for OS data were available from 8 trials [8, 9, 11–16]. No statistically significant improvement was shown in OS (HR = 0.94 [95% CI 0.86, 1.03], P = 0.16) (Fig 4), and there was no significant heterogeneity [χ² = 10.36, df = 7 (P = 0.16); I² = 32%]. Intercalated erlotinib plus chemotherapy treatment showed a modest but statistically significant improvement in OS (HR = 0.82 [95% CI 0.69, 0.98], P = 0.03) (Fig 5). Continuous erlotinib plus chemotherapy treatment failed to show an improvement in OS (HR = 0.98 [95% CI 0.89, 1.09], P = 0.75) (Fig 5). Subgroup analysis according to smoking status showed a statistically significant improvement in OS in never smoking patients (HR = 0.64 [95% CI 0.46, 0.89], P = 0.009) (Fig 5). Additionally, a statistically significant improvement in OS was observed in patients with EGFR mutant tumors (HR = 0.52 [95% CI 0.30, 0.88], P = 0.01) (Fig 5). No significant difference in OS was noted in patients with EGFR wild-type tumors (HR = 0.78 [95% CI 0.59, 1.01], P = 0.06) (Fig 5).

Adverse events

Data for the grade 3 or 4 adverse events were available in five studies [9–11, 15, 16]. There were more incidences of grade 3 or 4 anemia (OR = 1.48 [95% CI 1.12, 1.97], P = 0.006), rash
OR = 12.34 [95% CI 5.65, 26.95], P < 0.00001), and diarrhea (OR = 4.25 [95% CI 2.16, 8.38], P < 0.0001) in the erlotinib and chemotherapy combination treatment. However, there was no
difference in incidences of grade 3 or 4 neutropenia (OR = 1.02 [95% CI 0.83, 1.24], P = 0.86),
leucopenia (OR = 1.31 [95% CI 0.80, 2.14], P = 0.29), or thrombocytopenia (OR = 1.26 [95%
CI 0.91, 1.74], P = 0.17). Forest plots are shown in S1 Fig. The complete results are presented in
S1 Table.

Discussion

Over the past 20 years, chemotherapy has been the standard treatment for NSCLC. However,
the survival benefit of chemotherapy is not significant. Many studies have attempted to
improve the efficacy of chemotherapy by adding either another chemotherapeutic agent or a
targeted agent to the treatment regimen. This meta-analysis of currently available data demon-
strated that the combination of chemotherapy and erlotinib showed an improvement in PFS
for advanced NSCLC. There was no evidence that the combination of chemotherapy and
erlotinib improved OS when compared with chemotherapy alone. This is consistent with two
previous systematic reviews, which also demonstrated that the addition of EGFR TKIs to che-
motherapy showed an improvement in PFS, but not in OS [24, 25]. However, they did not ana-
lyze the efficacy of different schedules of erlotinib in combination with chemotherapy.

In subgroup analysis, intercalated erlotinib in combination with chemotherapy demon-
strated improvements in both PFS and OS compared with chemotherapy alone. Previously, a
randomized phase II study comparing intercalated erlotinib plus chemotherapy treatment to
erlotinib alone also showed a significant improvement in OS [26]. In another randomized
study, intercalated erlotinib plus pemetrexed showed 1.6-fold longer PFS compared with peme-
trexed alone [17]. This intercalated therapy avoided the G1 arrest by erlotinib, thus optimizing
the cell-cycle phase-dependent activity of chemotherapy. In other words, these data demon-
strate that intercalated therapy is the most effective combinatorial strategy. This combinatorial
strategy may benefit patients who have little benefit from EGFR-TKIs monotherapy [27]. In
this meta-analysis, continuous erlotinib plus chemotherapy versus chemotherapy alone failed
to show improvements in PFS and OS. A previous systematic review demonstrated that the
addition of EGFR TKIs to platinum-based first-line chemotherapy did not significantly
improve overall survival or time-to-disease progression [28]. The trials included in that system-
atic review all used continuous therapy strategy, which could partly explain the lack of benefit.
This is also consistent with the theory that EGFR-TKIs cause G1 cell-cycle arrest, which inhib-
its the cell-cycle-dependent cytotoxic effects of chemotherapy. In this study, the trials included
in the continuous therapy subgroup all dominantly enrolled Caucasian patients, which might be another reason for failure to show efficacy because previous studies had shown that Asian origin was a significant independent predictor for survival in EGFR-TKIs treatment [7]. Compared to Asian patients, Caucasian patients showed lower efficacy from oral EGFR-TKIs [29]. Similarly, this meta-analysis demonstrated that EGFR mutation was an important predictive biomarker for this treatment strategy. Among patients with EGFR mutant tumors, chemotherapy plus erlotinib demonstrated significant improvements in PFS (HR = 0.31 [95% CI 0.17, 0.58]) and OS (HR = 0.52 [95% CI 0.30, 0.88]). These data confirm the results of a previous phase II single arm clinical trial which showed that an intermittent schedule of erlotinib and
gemcitabine-based chemotherapy improved survival for patients with EGFR gene activating mutations [30]. Currently, several EGFR-TKIs such as erlotinib and gefitinib have been suggested as first-line treatments for patients with advanced EGFR mutation-positive NSCLC [31]. In this meta-analysis, no significant difference in PFS was found between the chemotherapy plus erlotinib group and the chemotherapy group in patients with EGFR wild-type tumors. Similarly, a previous single-arm study failed to demonstrate an add-on effect of intermittent erlotinib with pemetrexed as a second-line treatment for patients with non-squamous NSCLC without EGFR mutations [32]. The association of chemotherapy plus erlotinib with improvement in PFS was significant in non-smokers, but it was not statistically significant in smokers. Previous studies showed that a history of not smoking was also a significant independent predictor for survival in EGFR-TKIs treatment [7].

The meta-analysis demonstrated a longer PFS in patients who received erlotinib plus chemotherapy, showing a high heterogeneity level ($\chi^2 = 42.23, df = 8 \ (P = 0.006); I^2 = 81\%$) (Fig 2). To further explore this heterogeneity, we conducted subgroup analysis according to ethnicity. For PFS in Asian-dominant populations, HR = 0.55 [95% CI 0.47, 0.64] and the heterogeneity disappeared ($\chi^2 = 0.83, df = 3 \ (P = 0.66); I^2 = 0\%$) (Fig 3). For PFS in Caucasian-dominant populations, HR = 0.93 [95% CI 0.84, 1.03] and the heterogeneity decreased ($\chi^2 = 6, df = 5 \ (P = 0.31); I^2 = 17\%$) (Fig 3). Therefore, ethnicity could be the main reason for high heterogeneity. In subgroup analysis of intercalated combination of chemotherapy and erlotinib versus chemotherapy alone, there was also a high heterogeneity level ($\chi^2 = 14.28, df = 4 \ (P = 0.006); I^2 = 72\%$). When we excluded two studies that predominantly enrolled Caucasian populations, the heterogeneity disappeared ($\chi^2 = 0.83, df = 2 \ (P = 0.66); I^2 = 0\%$). Therefore, we believe that ethnicity is also the origin of this heterogeneity.

The present systematic review has some limitations. First, data could not be obtained from two included studies despite our contact with the primary investigators [17, 33]. Second, some trials such as TRIBUTE [16] enrolled 934 Caucasian patients and 154 others, while FASTACT [14] enrolled 145 Asian patients and 6 Caucasian patients. Due to limited data, we were unable to perform a pooled analysis according to ethnicity. To explore a high heterogeneity level in total PFS, we conducted subgroup analysis according to dominant ethnicity. What is more, given the probable bias due to the overlap of never smokers and EGFR mutants, data on never smokers are likely influenced by higher rate of EGFR mutants, since only 601 patients had EGFR status evaluated. We conclude that the combination of chemotherapy and erlotinib is a viable treatment option for patients with EGFR mutation. However, for patients with EGFR mutation-positive NSCLC, the current standard care is EGFR TKI alone. OPTIMAL study showed that compared with chemotherapy, erlotinib demonstrated a significant benefit in patients with advanced EGFR mutation-positive NSCLC, and median PFS was 13.1 months for erlotinib-treated patients versus 4.6 months for patients receiving chemotherapy [31]. In FASTACT-2, patients with EGFR mutation derived benefit from the combination treatment, and median PFS was 16.8 months [11]. We didn’t address whether a combination treatment was better than erlotinib alone for patients with EGFR mutation-positive NSCLC. A head-to-head study is needed to answer this question. In this systematic review, we analyzed the efficacy of different schedules of erlotinib in combination with chemotherapy, and led to a conclusion that the intercalated schedule showed an improvement in PFS and OS, while the continuous schedule did not.

In conclusion, the combination of chemotherapy and erlotinib is a viable treatment option for patients with NSCLC, and intercalated administration is an effective combinatorial strategy. This treatment strategy could benefit patients who never smoked and patients with EGFR mutation-positive disease. As this treatment strategy was more toxic, it warrants further investigation.
Supporting Information

S1 PRISMA Checklist. PRISMA Checklist for this Review.
(DOC)

S1 Fig. Forest Plot of Meta-analysis for Grade 3/4 AEs.
(TIF)

S1 Table. Comparison of Grade 3/4 AEs between Erlotinib plus Chemotherapy and Chemotherapy Alone.
(DOC)

S1 File. A list of full-text excluded articles.doc.
(DOC)

Acknowledgments

We thank Jun Xia and her colleagues for their support and guidance throughout the project.

Author Contributions

Conceived and designed the experiments: BHH JLX. Performed the experiments: JLX BJ ZHR YQL ZRZ BHH. Analyzed the data: YQL JLX. Contributed reagents/materials/analysis tools: JLX BJ ZHR YQL ZRZ BHH QZY. Wrote the paper: JLX BHH.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11–30. doi:10.3322/caac.21166 PMID: 23335087
2. Reck M, Popat S, Reimnuth N, De Ruyscher D, Kerr KM, Peters S, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3: ii27–39. doi:10.1093/annonc/mdu199 PMID: 25113505
3. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non–small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011; 364: 947–955. doi:10.1056/NEJMct0807960 PMID: 21388312
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69–90. doi:10.3322/caac.20107 PMID: 2196655
5. Zhang W, Lei P, Dong X, Xu C. The new concepts on overcoming drug resistance in lung cancer. Drug Des Devel Ther. 2014; 8: 735. doi:10.2147/DDDT.S60672 PMID: 24944510
6. Rossi A, Chiodini P, Sun J-M, O'Brien ME, von Plessen C, Barata F, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014; 15: 1254–1262. doi:10.1016/S1470-2045(14)70402-4 PMID: 25232001
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med. 2005; 353: 123–132. PMID:16014882
8. Michael M, White SC, Abdi E, Nott L, Clingan P, Zimet A, et al. Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS 2 patients with advanced NSCLC. Asia Pac J Clin Oncol. 2014.
9. Dittrich C, Papai-Szekely Z, Vinolas N, Sederholm C, Hartmann JT, Behringer D, et al. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer. Eur J Cancer. 2014; 50: 1571–1580. doi:10.1016/j.ejca.2014.03.007 PMID: 24705574
10. Aulliac JB, Choudat C, Greiller L, Monnet I, Le Caer H, Falchero L, et al. Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study. Lung Cancer. 2014; 85: 415–419. doi:10.1016/j.lungcan.2014.07.006 PMID: 25082565
11. Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a
randomised, double-blind trial. Lancet Oncol. 2013; 14: 777–786. doi: 10.1016/S1470-2045(13)70254-7 PMID: 23782814

12. Stinchcombe TE, Roder J, Peterman AH, Grigorieva J, Lee CB, Moore DT, et al. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2013; 8: 443–451. doi: 10.1097/JTO.0b013e3182835577 PMID: 23370367

13. Lee DH, Lee JS, Kim SW, Rodrigues-Pereira J, Han B, Song XQ, et al. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. Eur J Cancer. 2013; 49: 3111–3121. doi: 10.1016/j.ejca.2013.06.035 PMID: 23890768

14. Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27: 5080–5087. doi: 10.1200/JCO.2008.21.5541 PMID: 19738125

15. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007; 25: 1545–1552. PMID: 17442998

16. Herbst RS, Prager D, Herrmann F, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2013; 31.

17. Zheng Y, Xu N, Zhou J. Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? Lancet Oncol. 2013; 14: e438.

18. Xu J, Ren Z, Lou Y, Zhou Z, Huang L, Li Q, et al. Chemotherapy plus erlotinib versus chemotherapy for treating advanced non-small cell lung cancer (NSCLC). Prospero. 2014; CRD42014015015.

19. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151: 264–269. PMID: 19622511

20. Tierney JF, Stewart LA, Gheresi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16. PMID: 17555582

21. Stinchcombe TE, Peterman AH, Lee CB, Moore DT, Beaumont JL, Bradford DS, et al. A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥ 70 years) with stage IIIIB/IV non-small cell lung cancer. J Thorac Oncol. 2011; 6: 1569–1577. doi: 10.1097/JTO.0b013e3182210430 PMID: 21716146

22. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer patients: the NVALT–10 study. Ann Oncol. 2013; 24: 2860–2865. doi: 10.1093/annonc/mdt341 PMID: 23986090

23. Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, et al. Comparison of the efficacy and safety of EGFR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Med Oncol. 2015; 32: 471. doi: 10.1007/s12032-014-0471-0 PMID: 25579169

24. Zhou JG, Tian X, Wang X, Tian JH, Wang Y, Wang F, et al. Treatment on advanced NSCLC– platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials. Med Oncol. 2015; 32: 471. doi: 10.1007/s12032-014-0471-0 PMID: 25579169

25. Aerts J, Codrington H, Lankheit N, Burgers S, Biesma B, Dingemans A-M, et al. A randomized phase II study comparing erlotinib versus gefitinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT–10 study. Ann Oncol. 2013; 24: 2860–2865. doi: 10.1093/annonc/mdt341 PMID: 23986090

26. Feld R, Sridhar SS, Shepherd FA, Mackay JA, Evans WK. Use of the epidermal growth factor inhibitor gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol. 2006; 1: 367–376. PMID: 17409886

27. Ahn M-J, Lee J, Park Y-H, Ahn J-S, Ziogas A, Zell JA, et al. Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer
before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era. J Thorac Oncol. 2010; 5: 1185–1196. doi:10.1097/JTO.0b013e3181e2f624 PMID: 20592628

30. Zwitter M, Rajer M, Kovac V, Kern I, Vrankar M, Smrdel U. Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial. J Biomed Biotechnol. 2011; 2011: 185646. doi:10.1155/2011/185646 PMID: 21541241

31. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12: 735–742. doi:10.1016/S1470-2045(11)70184-X PMID: 21783417

32. Minami S, Kijima T, Hamaguchi M, Nakatani T, Koba T, Takahashi R, et al. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status. Lung Cancer. 2013; 82: 271–275. doi:10.1016/j.lungcan.2013.07.022 PMID: 23993733

33. Boutsikou E, Kontakiotis T, Zarogoulidis P, Darwiche K, Eleptheriadou E, Porpodis K, et al. Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. Onco Targets Ther. 2013; 6: 125. doi:10.2147/OTT.S42245 PMID: 23467839